# Synthesis, Crystal Structure and Biological Activity of 2-[(Pyridin-2-yl)methylthio]-1H-benzimidazole Derivatives

GAO Di(高迪)(1,2);CHEN Gu-Zhou(陈固洲)(②);CAO Sheng(曹 胜) (2);DU Yue(杜月) (2);JIN Zhe(金辄)(2);LIU Xiao-Ping(刘晓平)(2);OUYANG Gui-Ping(欧阳贵平) ();HU Chun(胡春) (1,2) (1 Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Research and Development Center of Fine Chemicals, Guizhou University, Guiyang 550025, China;2 (Key Laboratory of Structure-based Drug Design & Discovery, Ministry of Education; Shenyang Pharmaceutical University, Shenyang 110016, China

ABSTRACT Inordertodiscover thenovel anti-tumoragents，aseries of 2-[(pyridin-2-yl)methylthio]- $1 H$ -benzimidazole derivatives were designed and synthesized,and the structures were characterized by IR, MS, and proton NMR. 2-[(3,4-Dimethoxypyridin-2-yl)methylthio]-1H-benzimidazole was investigated with X-ray crystallography, and the molecule is in orthorhombic system, space group $P 2 _ { 1 } 2 _ { 1 } 2 _ { 1 }$ ,with $a = 9 . 1 8 2 8 ( 1 6 ) , l$ $= 1 1 . 6 2 5 ( 2 )$ ， $c = 1 3 . 4 6 3 ( 2 )$ A, $Z = 4$ $R = 0 . 0 2 3 1$ and $w R = 0 . 0 5 9 6$ . The antitumor activities of target compounds were evaluated against human liver cancer cel line HepG2,and human liver normal cel line HL7702 using MTT assay. The target compounds have demonstrated weak or moderate anti-tumor activity against HepG2, while all the target compounds exhibit no cytotoxic effects on HL7702.

Keywords: 2-[(pyridin-2-yl)methylthio]-1H-benzimidazole derivatives; synthesis; crystal structure; antitum0r activity; DOI: 10.14102/j.cnki.0254-5861.2011-1730

# 1 INTRODUCTION

Nowadays a large number of populations were affected by cancers allaround the world. Only in 2012,14.2 million new cancer cases and 8.2 milion deaths had happened unfortunately,and up to 2O3O it is reported to increase to about 19 million[1].

In recent decades,the benzimidazole derivatives were discovered to exhibit various biological activities suchasantibacterial，antiviral，antiallergic， cardiovascular，antitumor，analgesic,antiflammatory, $\mathrm { H ^ { + } / K ^ { + } }$ -ATPase inhibitory and antipyretic activities[2l.The benzimidazole derivatives with pyridyl group have reported to demonstrate potent anticancer and antitumor activities.For example，the benzimidazole derivatives with 2-pyridylethyl moiety at the 2-position displayed inhibitory effects on the proliferation of murine leukemia cels (L1210/O) and human T-lymphocyte cels (Molt 4/C8 and CEM/O) with the $\mathrm { I C } _ { 5 0 }$ values in the low microgram range[3，4]． Some 2-[3-(pyridin-3-yl)styryl] $1 H$ benzimidazole derivatives have exhibited antiproliferative activity against HeLa,HepG2,A498,MCF-7 and U937 cellines[5].The hybrid compounds with benzimidazole ring and pyridine skeleton were designed and evaluated against NCI 60 cell lines,and the screening results show some compounds exhibit a very good antitumor activity against renal cancer A498 and breast cancer MDA-MB-468 and also present a significant antitumor activity against leukemia (RPMI-8226, CCRF-CEM, K-562, SR), non-smallcell lung cancer (NCI-H23,A549/ATCC),and breast cancer T-47D[6].

According to the antitumor structure-activity relationship of benzimidazole derivatives，principle of bioisosterism and hybridization,a series of 2-[(pyridin-2-yl)methylthio]- $1 H \cdot$ benzimidazole derivatives were designed and synthesized as the target compounds.The synthesis of the target compounds is shown in Scheme 1, according to the reported procedurel[7-11].

![](images/dc1b683bc6ecbdad6a62d0f67aada120ac97027d30c1c3ec642868b157e5f541.jpg)  
Scheme 1. Synthesis of the target compounds

The target compounds were characterized by IR, proton NMR,and ESI-MS.Fortunately, a single crystal of a target compound was grown,and the structure was characterized by $\mathrm { \Delta } X$ -ray diffraction analysis.The preliminary pharmacological test showed all target compounds exhibit weak or moderate cytotoxicity against human liver cancer celline HepG2 and no cytotoxic effects on the human liver normal celline HL7702.

# 2 EXPERIMENTAL

# 2.1Apparatus and materials

The melting points were determined on a melting-point apparatus with microscope (Zhengzhou Mingyi Instrument Equipment Co.，Ltd.， Zhengzhou, China)，and were uncorrected. ESI mass spectra were performed on a Waters spectrometer (Waters Corporation, USA). The IR spectra were recorded on a Bruker IFS55 spectrometer (KBr pellets). $\mathrm { ^ { 1 } H }$ NMR spectra were recorded on a Bruker (40O MHz） NMR spectrometer (Faellanden, Switzerland) with TMS as an internal standard and $\mathrm { C D C l } _ { 3 }$ as the solvent. Chemical shifts ( $\delta$ values) and coupling constants ( $J$ values) are respectively given in ppm and Hz.

All the starting materials were commercially available and directly used without further purification. Al the reaction progress was monitored by thin layer chromatography analysis with the silica gel plates (Qingdao Jiyida silica reagent factory, Qingdao, China).

2-Chloromethyl-4-methoxy-3,5-dimethylpyridine hydrochloride,   
2-chloromethyl-3,4-dimethoxypyridine hydrochloride,   
2-chloromethyl-3-methyl-4-(2,2,2-trifluoroethoxyl)pyridine hydrochloride, and   
2-chloromethyl-4-(3-methoxypropoxy)-3-methylpyridinehydrochloridewerepreparedbypreviously   
reported procedures[7, 8].

# 2.2Synthesis and characterization

Amixtureof2-chloromethyl-4-methoxy-3,5-dimethylpyridinehydrochloride(0.0040mol), $1 H \cdot$ -benzimidazole-2-thiol (0.0040 mol)， $40 \%$ sodium hydroxide aqueoussolution $( 2 0 ~ \mathrm { ~ \ m L } )$ ）and dichloromethane ( $2 0 ~ \mathrm { m L }$ ）was refluxed for $1 5 \mathrm { h }$ .After cooling to room temperature,and partitioned between dichloromethane and water. The water layer was extracted with dichloromethane ( $3 { \times } 1 0 ~ \mathrm { m L }$ )，the organic layers were combined and dried over anhydrous magnesium sulphate， filtered,purified using column chromatography (V(petroleum ether): V(ethyl acetate) 公 1:1) to afford 2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylthio] $1 H \cdot$ -benzimidazole (3a,white solid, $9 9 . 1 \%$ purity）in $8 5 . 6 \%$ yield. m.p.: $1 2 4 . 0 { \sim } 1 2 6 . 6 \ ^ { \circ } \mathrm { C }$ EI-MS $( \mathbf { m } / \mathbf { z } )$ ： $3 0 0 . 1 ( 0 [ \mathrm { M } + \mathrm { H } ] ) ^ { + } ,$ ，322.1( $\mathrm { [ M + N a ] ^ { + } } ,$ ; IR(KBr): v 3577.9, 3133.6,3056.5,1618.6, 1592.8,1567.3,1501.8,1438.3,1270.1,1270.1,1227.1,875.1, 762.6,734.6; $\mathrm { ^ 1 H }$ NMR (400 MHz, Chloroform $\mathbf { \nabla } \cdot d$ ): δ 12.73 (s,1H),8.27 (s,1H), 7.62 (d, $J { = } 9 . 0 \mathrm { H z }$ , 1H), 7.45 (d, $J { = } 9 . 0 \mathrm { H z }$ 1H), $7 . 2 2 \sim 7 . 1 6$ (m,2H),4.37 (s,2H),3.79 (s,3H),2.33 (s,3H),2.28 (s,3H).   
Similarly， 2-[(3,4-dimethoxy-2-pyridinyl)methylthio]- $1 H \cdot$ -benzimidazole (3b） was prepared as a white solid in $8 5 . 6 \%$ yield. m.p.:1 $1 7 . 9 \mathrm { \sim } 1 2 0 . 0 ^ { \circ } \mathrm { C }$ EI-MS $_ \mathrm { m } / z$ )： 302.1( $[ \mathrm { M } \mathrm { + H } ] ^ { + } ,$ ; IR(KBr): $\nu$ 3421.3, 2971.7, 2881.1, 1640.5,1585.6,1489.0, 1302.8,1266.2, 1232.4, 1067.5, 820.7, 746.6. $\mathrm { ^ { 1 } H }$ NMR (400 MHz, Chloroform-d): $\delta$ 13.01 (s, 1H), 8.28 (d, $\mathbf { J } = 5 . 6 \mathrm { H z }$ ,1H),7.62 (s,1H),7.49 (s,1H),7.19 (dd, $\mathrm { J } = 6 . 0$ ， $3 . 2 \ : \mathrm { H z }$ ,2H), 6.87 (d, ${ \bf { J } } =$ 5.6 Hz,1H),4.40 (s,2H), 3.95 (s,3H), 3.94 (s, 3H).   
2-{[(3-Methyl-4-(2,2,2-trifluoroethoxyl)-2-pyridinyl)]methylthio}- $1 H$ -benzimidazole $( { \bf 3 . c } )$ was prepared as a white solid in $8 8 . 0 \%$ yield. m.p: $1 4 9 . 3 { \sim } 1 5 0 . 5 ~ ^ { \circ } \mathrm { C } ( \mathrm { l i t } ^ { [ 7 ] }$ $1 4 9 { \sim } 1 5 0 ~ ^ { \circ } \mathrm { C } ;$ .EI-MS $\langle \mathbf { m } / \mathbf { z } \rangle$ ： 354.1( $[ \mathrm { M } \mathrm { + H } ] ^ { + } \backslash$ ： IR(KBr): $\nu$ 3135.1,3052.5,2976.3,2896.6,2844.4, 1618.5,1589.8, 1577.9, 1444.2,1269.1, 1163.6, 1174.2, 1110.4, 857.9, 746.0; $^ 1 \mathrm { H }$ NMR ( ${ \bf \Psi } _ { 4 0 0 } \bf { M H z }$ ,Chloroform-d): $\delta$ 12.57 (s, 1H), 8.43 (d, $\mathbf { J } = 5 . 5 \mathrm { { H z } }$ ,1H), 7.62 (s, 1H), 7.46 (s,1H), 7.19 (dd, $\mathbf { J } = 6 . 0$ ,3.1 Hz,2H), 6.74 (d, $\mathbf { J } = 5 . 6 \mathrm { H z }$ ,1H), 4.45 (m,1H), 4.42 (s,2H),2.33 (s, 3H).   
2-{[(4-(3-Methoxypropoxy)-3-methyl-2-pyridinyl]methylthio}- $1 H$ -benzimidazole (3d) was prepared as a white solid in $7 7 . 0 \%$ yield. m.p: $1 0 5 . 1 { \sim } 1 0 6 . 0 ^ { \circ } \mathrm { C } .$ EI-MS $[ \mathrm { m } / \mathrm { z } ]$ ： 344.1( $[ \mathrm { M } \mathrm { + H } ] ^ { + } ,$ ); IR(KBr): v 3420.1, 3267.0, 3098.9,2966.6,2925.0,2837.3,1625.5,1599.0,1550.3,1510.0,1464.4,1382.4,1360.8,1323.2. 1303.4, 1260.4, 1176.3, 1164.01121.3. $\mathrm { ^ { 1 } H }$ -NMR ( $4 0 0 \mathrm { { M H z } }$ ,chloroform-d): $\delta 8 . 1 2$ (d, $J { = } 8 . 9 \mathrm { H z }$ ,2H), 7.54 (d, $J = 8 . 6$ Hz, 1H), $7 . 0 9 \sim 6 . 9 0$ (m, 4H), $4 . 1 4 \mathrm { \sim } 4 . 0 0$ (m,3H), 3.90 (s, 3H), $2 . 9 5 { \sim } 2 . 8 8$ (m,1H), 2.84 (dt, $J = 1 2 . 5$ ，6.3 Hz, 1H), $2 . 7 8 { \sim } 2 . 7 1$ (m,1H),2.60 (s,3H), 1.10 (d, $J = 6 . 3 \mathrm { H z } ,$ 6H).

# 2.3Crystal structure determination

The target compound 3b was taken a bit into a conical flask,dissolved by methanol/acetone ( $V / V = 1 / 1$ ） mixture.The botleneck of the flask was sealed for volatilizing slowly by plastic film.The white single crystals of the target compound 3b ( $\mathrm { 0 . 2 4 m m \times 0 . 2 2 m m \times 0 . 1 8 m m }$ used for $\mathrm { \Delta } X$ -ray crystallographic analysis was obtained after 7 days.The data of 3b were collected by a Rigaku O07HF Xta LAB P2OO diffractometer equipped with a graphite-monochromatic $\mathbf { M o } K \alpha$ radiation $\overset { \cdot } { \lambda } = 0 . 7 1 0 7 3 \overset { \circ } { \mathrm { A } }$ ）using an $\omega$ scan mode at $1 1 3 \mathrm { ~ K ~ }$ In the range of $3 . 0 { \leqslant } \theta { \leqslant } 2 7 . 5 ^ { \circ }$ ， a total of 18516 reflections were collcted with 5388 unique ones ( $R _ { \mathrm { i n t } } =$ 0.0347),of which 3181 $( - 1 1 \leqslant h \leqslant 1 1$ ， $- 1 5 \leqslant k \leqslant 1 5$ ， $- 1 6 \leqslant l \leqslant 1 7$ ）were observed with $I > 2 \sigma ( I )$ and used in the succeeding refinements. The intensity data were corrected for $L \boldsymbol { p }$ factors and empirical absorption. The structure was resolved by direct methods and expanded by diffrence Fourier techniques with SHELXL and SHELXS programs[12-141. All of the non-hydrogen atoms were located with successve difference Fourier syntheses. The structure was refined by full-matrix least-squares techniques on $F ^ { 2 }$ using anisotropic thermal parameters for all non-hydrogen atoms. The hydrogen atoms were added according to theoretical models. The final cycle of refinement converts to $\ell = 0 . 0 2 3 1 , w R = 0 . 0 5 9 6 \ ( w = 1 / [ \sigma ^ { 2 } ( F _ { o } ^ { 2 } ) + ( 0 . 0 3 6 0 P ) ^ { 2 } + 0 . 1 4 1 1 P ] ,$ （20 where $P = ( { F _ { o } } ^ { 2 } + 2 { F _ { c } } ^ { 2 } ) / 3 .$ ）， $S = 1 . 0 7 3$ ， $( \Delta / \sigma ) _ { \mathrm { { m a x } } } = 0 . 0 3 5$ ， $( \Delta \rho ) _ { \mathrm { m a x } } = 0 . 1 9 1$ ,and $( \Delta \rho ) _ { \mathrm { m i n } } = - 0 . 1 6 8 \mathrm { e } \cdot \mathring { \mathrm { A } } ^ { - 3 }$

# 2.4Antitumor activity

Human liver cancer celline HepG2 and human liver normal celline HL77O2 were used to evaluate the anti-tumor activity of target compounds in vitro by MTT assay with 5-fluorouracil as the positive control[15. 16l. HepG2 and HL7702 cels were harvested in the logarithmic growth phase and seeded in 96-well plates at a density of 8OOO cells per well,and cultured at $3 7 ~ ^ { \mathrm { { o } } } \mathrm { { C } }$ in humidified atmosphere containing $5 \%$ $\mathrm { C O } _ { 2 }$ in Dulbecco's modified Eagle's medium (DMEM or RPMI-1640) with $10 \%$ fetal bovine serum (FBS) for $2 4 \mathrm { h }$ before any treatments.The tested compounds were dissolved in DMSO and diluted in the culture fluid to get various concentrations. The cells were treated with target compounds subsequently and incubated overnight. Then $2 0 ~ \mu \mathrm { L }$ of MTT ( $5 ~ \mathrm { m g / m L }$ ） was added in each well and after $^ { 4 \mathrm { ~ h ~ } }$ incubation, the medium was removed immediately and MTT formazan was solubilized in $1 5 0 ~ \mu \mathrm { L }$ of DMSO. The optical densities(OD） were measured with a microplate reader (Bio-Tek instruments, INC. USA） at $4 9 0 ~ \mathrm { n m }$ .Inhibitory effects were expressed as the percentage of inhibition. Each assay was performed thrice.

# 3 RESULTSANDDISCUSSION

# 3.1 Molecular structure

The crystal structure of the target compound 3b ( $\mathrm { 0 . 2 4 m m \times 0 . 2 2 m m \times 0 . 1 8 m m }$ ）was confirmed by $\mathrm { \Delta } X$ -ray diffraction analysis. The target compound 3b crystallizes in orthorhombic,space group $P 2 _ { 1 } 2 _ { 1 } 2 _ { 1 }$ with $a =$ 9.1828(16), $b = 1 1 . 6 2 5 ( 2 )$ ， $c = 1 3 . 4 6 3 ( 2 ) \mathring { \Delta }$ ， $V = 1 4 3 7 . 2$ (5) $\mathring { \mathbf { A } } ^ { 3 }$ $Z = 4$ $\mathrm { C _ { 1 5 } H _ { 1 5 } O _ { 2 } N _ { 3 } S }$ $D _ { c } = 1 . 3 9 3 ~ \mathrm { g } { \cdot } \mathrm { c m } ^ { - 3 }$ $\mu =$ $0 . 2 3 3 ~ \mathrm { m m } ^ { - 1 }$ ， $F ( 0 0 0 ) = 6 3 2$ ， $S = 1 . 0 7 3$ ， $R = 0 . 0 2 2 2$ and $w R = 0 . 0 5 9 3$ for 3181 independent reflections $( { \mathrm { R i n t } } =$ 0.0347) with $\mathrm { I } > 2 \sigma ( \mathrm { I } ) $ .The selected bond distances and bond angles are listed in Table 1.

Table 1. Selected Bond Lengths $( \mathring \mathbf { A } )$ and Bond Angles ${ \bf \Pi } ^ { \circ } )$ for Compound 3b   

<html><body><table><tr><td>Bond</td><td>Dist.</td><td>Bond</td><td>Dist.</td><td>Bond</td><td>Dist.</td></tr><tr><td>S(1)-C(1)</td><td>1.8091(16)</td><td>N(2)-C(9)</td><td>1.311(2)</td><td>C(5)-C(6)</td><td>1.386(3)</td></tr><tr><td>S(1)-C(9)</td><td>1.7489(16)</td><td>N(2)-C(15)</td><td>1.396(2)</td><td>C(10)-C(11)</td><td>1.394(2)</td></tr><tr><td>0(1)-C(3)</td><td>1.3740(18)</td><td>N(3)-C(2)</td><td>1.347(2)</td><td>C(10)-C(15)</td><td>1.404(2)</td></tr><tr><td>0(1)-C(7)</td><td>1.436(2)</td><td>N(3)-C(6)</td><td>1.337(2)</td><td>C(11)-C(12)</td><td>1.384(2)</td></tr><tr><td>0(2)-C(4)</td><td>1.3513(19)</td><td>C(1)-C(2)</td><td>1.512(2)</td><td>C(12)-C(13)</td><td>1.395(3)</td></tr><tr><td>0(2)-C(8)</td><td>1.437(2)</td><td>C(2)-C(3)</td><td>1.387(2)</td><td>C(13)-C(14)</td><td>1.385(3)</td></tr><tr><td>N(1)-C(9)</td><td>1.362(2)</td><td>C(3)-C(4)</td><td>1.400(2)</td><td>C(14)-C(15)</td><td>1.401(2)</td></tr><tr><td>N(1)-C(10)</td><td>1.385(2)</td><td>C(4)-C(5)</td><td>1.392(2)</td><td></td><td></td></tr><tr><td>Angle</td><td>（）</td><td>Angle</td><td>(）</td><td>Angle</td><td></td></tr><tr><td>C(9)-S(1)-C(1)</td><td>100.84(8)</td><td>C(2)-C(3)-C(4)</td><td>119.38(14)</td><td>N(1)-C(10)-C(15)</td><td>105.28(13)</td></tr><tr><td>C(4)-0(2)-C(8)</td><td>117.52(13)</td><td>0(2)-C(4)-C(3)</td><td>116.11(14)</td><td>C(11)-C(10)-C(15)</td><td>122.22(15)</td></tr><tr><td>C(9)-N(1)-C(10)</td><td>105.87(13)</td><td>0(2)-C(4)-C(5)</td><td>125.68(15)</td><td>C(12)-C(11)-C(10)</td><td>116.91(16)</td></tr><tr><td>C(9)-N(2)-C(15)</td><td>103.57(13)</td><td>C(5)-C(4)-C(3)</td><td>118.21(14)</td><td>C(11)-C(12)-C(13)</td><td>121.36(16)</td></tr></table></body></html>

<html><body><table><tr><td>C(6)-N(3)-C(2)</td><td>117.09(14)</td><td>C(6)-C(5)-C(4)</td><td>117.97(15)</td><td>C(14)-C(13)-C(12)</td><td>122.02(16)</td></tr><tr><td>C(2)-C(1)-S(1)</td><td>114.49(11)</td><td>N(3)-C(6)-C(5)</td><td>124.65(15)</td><td>C(13)-C(14)-C(15)</td><td>117.40(17)</td></tr><tr><td>N(3)-C(2)-C(1)</td><td>118.78(13)</td><td>C(3)-0(1)-C(7)</td><td>113.77(12)</td><td>N(2)-C(15)-C(10)</td><td>110.32(14)</td></tr><tr><td>N(3)-C(2)-C(3)</td><td>122.64(14)</td><td>N(1)-C(9)-S(1)</td><td>118.55(12)</td><td>N(2)-C(15)-C(14)</td><td>129.61(16)</td></tr><tr><td>C(3)-C(2)-C(1)</td><td>118.58(14)</td><td>N(2)-C(9)-S(1)</td><td>126.48(12)</td><td>C(14)-C(15)-C(10)</td><td>120.07(15)</td></tr><tr><td>0(1)-C(3)-C(2)</td><td>120.18(13)</td><td>N(2)-C(9)-N(1)</td><td>114.97(14)</td><td></td><td></td></tr><tr><td>0(1)-C(3)-C(4)</td><td>120.35(14)</td><td>N(1)-C(10)-C(11)</td><td>132.50(16)</td><td></td><td></td></tr></table></body></html>

The molecular structures and crystal packing pictures were drawn by the Diamond program[17]. One structure unit of 3b is shown in Fig.1. The molecular packing for 3b viewed along the $a$ axis is depicted in Fig. 2.

![](images/096335b0768fa58b5f5908bf00b9d6ef00a2a4ad587876b8b7997da6879c57eb.jpg)  
Fig.1. Structure unit of 3b,showing the atom numbering scheme

![](images/c7433fc60097c4ce52a7d172d277679c022d57abc2a4fa053c76dd53273722a1.jpg)  
Fig.2.Molecular packing for 3b

There are some weak interactions (donor-H…acceptor interactions,D-HA interactions, including N-H…N, C-H…O, C-H…S, C-H…N, $\mathrm { C - H } \cdots \pi$ interactions） observed in Fig. 3 by using the Mercury program[18], with the red dashed lines indicating the interactions.The weak interactions are listed in Table 2.

![](images/12eeec0fb7471da0caae3ca7ae546e67b78ae63130347cbeefa31f995877a01e.jpg)  
Fig.3.Part of the crystal structure of 3b.D-H.A interactions are shown with red dashed lines

Table 2. Weak D-H.AInteractions of 3b   

<html><body><table><tr><td>D-HA</td><td>d (D-H) (A)</td><td>d (HA) (A)</td><td>d (DA) (A)</td><td>Angle (D-HA) (°)</td><td>Symmetry codes</td></tr><tr><td>N(1)-H(1)…·N(3)i)</td><td>0.8330(215)</td><td>2.0911(216)</td><td>2.9192(20)</td><td>172.675(2066)</td><td>(i)-1/2+x,1/2-y,1-z</td></tr><tr><td>C(1)-H(1B)…·O(1)</td><td>0.9900(16)</td><td>2.3447(11)</td><td>2.8046(20)</td><td>107.400(97)</td><td></td></tr><tr><td>C(6)-H(6)·S(1)i)</td><td>0.9496(17)</td><td>2.8873(6)</td><td>3.6781(18)</td><td>141.471(104)</td><td>(i) -1/2+x, 1/2-y, 1-z</td></tr><tr><td>C(8)-H(8B).O(1)(i)</td><td>0.9797(19)</td><td>2.4740(11)</td><td>2.8660(22)</td><td>103.528(112)</td><td>(ii) -1/2+x, 1/2-y,-z</td></tr><tr><td>C(11)-H(11).S(1)(i)</td><td>0.9500(17)</td><td>2.8339(5)</td><td>3.4307(18)</td><td>121.782(105)</td><td>(i) 1/2+x,1/2-y,1-z</td></tr><tr><td>C(12)-H(12)··N(2)(iv)</td><td>0.9499(18)</td><td>2.5018(13)</td><td>3.3565(22)</td><td>149.720(112)</td><td>(iv) 1-x, -1/2+y, 1/2-z</td></tr><tr><td>C(7)-H(7C).·C(9)()</td><td>0.9803(18)</td><td>2.8540(15)</td><td>3.4371(24)</td><td>118.935(109)</td><td>(v) 2-x,-1/2+y,1/2-z</td></tr></table></body></html>

# 3.2 Antitumor activity

Using 5-fluorouracil as a positive control, the target compounds were evaluated forthe cytotoxic activities in vitro against human liver cancer cell line HepG2 and human liver normal celline HL77O2 by MTT colorimetric assay.The in vitro inhibitory activity results of the target compounds are summarized in Table 3.

Table 3.Inhibitory Activityin vitro of the Target Compounds   

<html><body><table><tr><td rowspan="2">Compound</td><td colspan="2">Inhibition rate (%) (50 μM)</td></tr><tr><td>HepG2</td><td>HL7702</td></tr><tr><td>3a</td><td>13.27</td><td>0.40</td></tr><tr><td>3b</td><td>28.54</td><td>1.96</td></tr><tr><td>3c</td><td>34.52</td><td>1.75</td></tr><tr><td>3d</td><td>22.29</td><td>2.21</td></tr><tr><td>5-Fluorouracil</td><td>100</td><td>7.33</td></tr></table></body></html>

These results show the target compounds exhibit weak or moderate cytotoxic activity against HepG2, and

allte target compounds almost do not exhibit cytotoxic efects on HL77O2.These results have revealed that the target compounds show excellent selective activity against the malignant tumor ce line.

# 4 CONCLUSION

A series of 2-[(pyridin-2-yl)methylthio]- $1 H$ -benzimidazole derivatives were designed, synthesized and characterized byIR，MS，and proton NMR, and the target compound 2-[(3,4-dimethoxypyridin-2-yl)methylthio]- $1 H$ -benzimidazole (3b) was investigatedwithX-ray crystallography. The antitumor activities of target compounds were evaluated for the cytotoxic activities against human liver cancer celline HepG2,and human liver normal celline HL77O2 using MTT assay. The cytotoxicity assay results have showed that these target compounds exhibit weak or moderate anti-tumor activity against HepG2，while all the target compounds exhibit no cytotoxic effects on HL77O2，which implies that the target compounds show excellent selective activity against the malignant tumor cel line.

ACKNOWLEDGEMENT The authors would like to thank Crystal Impact GbR Ltd. Co. and Cambridge Crystallographic Data Centre (CCDC) for kindly providing us with a free evaluation of their software packages,Diamond and Mercury. The software packages would be used strictly for individual research or teaching use.The authors thank Prof.Hai-Bin Song from Nankai University for crystal structure analysis.

# REFERENCES

(1） Biemar.F.;Foti,M.Global progressagainstcancer—challengesandopportunities.Cancer BiologyMed.20l3,10,183-186.   
(2) Spasovic properties.Pharm. Chem.J.1999,33,232-243.   
(3) GrutiLbelllell N-benzenesulphonyl-2(2-or 3-pyridylethyl)benzimidazoles.Anti-cancer Drug Des.1998,13,397-406.   
(4) Garuti,L;obrt,;D,isialfactifoaod Lett 2002,12,2707-2710.   
(5) Buscat6,Ee B.;Proschak,E.Froultiotentstinetolubleoxiderolaseiosithtiproiferatiepropertis.eed 919-923.   
(6) YadavS.;arasKauspifoliaetsirneetsdC 2015,16, 1403-1425.   
(7）Kohl,B.;Sturm,E.;Sen-Bilfinger,J.;Simon,W.A.;Kruger,U.;Schaefer,H.;Rainer,G.;igala,V.;Klemm,K. $( \mathrm { H } ^ { + } , \mathrm { K } ^ { + } )$ -ATPase inhibiting 2[(2-pyrdsulfdlsoefodubsitedoiadeeiiy of pantoprazole as a clinical candidate.J.Med. Chem.1992,35,1049-1057.   
(8）LiuXP;

LatinAm.J.Pharm.2015,34,1265-1268.

(9）Zhang,L.;Xu,H.L.;Deng,X.S.;Liu,C.C.;Liu,X.P.;Hu,C.SynthesisofimpurityBofEsomeprazole.FineChem.Itermed 2015，45，17-19.   
(10）Kamisowtlyfadsii imidazodaamptiolaalisdliteo Chem.1997,40,427-436.   
(11）TerauchiH;Taitame,A.;Tada,K;kara,K.;Seto,Y;shikawa,cotiaidederivativssecaoftic $\mathrm { H } { + } / \mathrm { K } ( { + } )$ -ATPase iibitors..tisdructureactiieatiossfbstiteddrsulcotas.d. 40, 313-321.   
(12）Sheldrick,GM.SHELL97.ProgramfortheRefinementofCrystaltructures.UniversityofGotingen:Gotingen,Geany1997.   
(13）Sheldrick,G.M.A short history of SHELX.Acta Cryst.A2008,64,112-122.   
(14）Sheldrick,G.M. Crystal structure refinement with SHELXL.Acta Cryst. C 2015,71,3-8.   
(15）Mosaapidrcfoellaohdal:aatiotroliadoiss. 1983, 65, 55-63.   
(16）Beidge,Taaceofde subcelularocalzatiosubstrateepdedvolentofitocodactrontrasprtiductioAchoh 1993,303,474-482.   
(17）BergerotKaacaJ. 1996, 101, 221-225.   
(18）MacraeCdgocabco,E;esloowerualzaiais crystal structures.J.Appl. Cryst. 2006,39,453-457.

# Synthesis, Crystal Structure and Biological Activity of 2-[(Pyridin-2-yl)methylthio]-1H-benzimidazole Derivatives

GAO Di(高迪）CHENGu-Zhou(陈固洲）CAO Sheng(曹胜）DU Yue(杜月）JIN Zhe(金辄）LIU Xiao-Ping(刘晓平） OUYANG Gui-Ping(欧阳贵平） HUChun(胡春)

![](images/aeb83e85256e7f882bdda7752fe9d8da17e002b2b74cba88c074b1bbbff3dd12.jpg)

A series of 2-[(pyridin-2-yl)methylthio]- $1 H$ -benzimidazole derivatives were designed and synthesized, and the structures were characterized by IR， MS, and proton NMR. 2-[(3,4-Dimethoxypyridin-2-yl)methylthio]-1H-benzimidazole was investigated with $\mathrm { \Delta } \mathrm { X }$ -ray crystallography.

Antitumor activities of the target compounds were evaluated against human livercancer celline HepG2,and human liver normal cell line HL7702 using MTT assay.The target compounds demonstrate weak or moderate anti-tumor activity against HepG2,but no cytotoxic effects on HL7702.